In vivo Efficacy Models

Banner image with various scientific toolsAntibacterial

Septicemia Infection (Mouse)

  • Determinations of Median Effective Dose (ED50) and bacterial tissue titers for test articles against infections with both gram-positive and gram-negative pathogens, including characterized resistant strains.

Subcutaneous Abscess (Mouse)

  • A chronic skin infection model using either S. aureus (MRSA), S. epidermidis(MRSE), S. pyogenesor P. aeruginosa bacterial isolates.

Superficial Skin Infection Model (Mouse)

  • A superficial skin infection model for the determination of efficacy of topical agents using either S. aureusS. pyogenes, P. aeruginosa orA. baumannii individual and mixed infections.

Biofilm Catheter Implant (Mouse)

  • Model of device-related biofilm infection using subcutaneous S. aureus infected teflon catheter implants. Gram-negative organisms in development.

Prosthetic Joint Infection (Mouse)

  • Implant associated infection with a femoral pin (stainless steel) – S. aureus infection

Acute Lung Infection (Mouse)

  • Murine lung infections with S. aureusS. pneumoniae, K. pneumoniae, A. baumannii, P. aeruginosa and H. influenzae using bacterial lung titers and/or survival as measured endpoints.

Acute Lung Infection (Rabbit)

  • Lung infections with K. pneumoniae and P. aeruginosa using bacterial lung titers and/or survival as measured endpoints.

Chronic Lung Infection (Mouse)

  • P. aeruginosa & S. aureus (MRSA)

Central Venous Catheter Infection (Rat)

  • Biofilm infection of an intravascular indwelling jugular catheter with S. aureus

Granuloma Pouch (Rat / Mouse)

  • Infected pouch model for the simultaneous determination of penetration (levels) and efficacy (CFU counts) of administered agents in the rat or mouse.

Helicobacter pylori Gastritis (Mouse)

  • Gastric infection model using H. pyloristrains with efficacy measured as CFU log reduction / relapse within the gastric mucosa.

Clostridium difficile Infection (Hamster & Mouse)

  • CDAD model for the evaluation of survival / relapse, GI pharmacokinetics, fecal/cecal bacterial titers and Tox A/B detection utilizing both susceptible and epidemic (Ribotypes 027 & 078) clinical isolates.

Neutropenic Thigh Infection Model (Mouse)

  • Determination of the Pharmacokinetic / Pharmacodynamic indices as related to the efficacy of an antimicrobial agent (pharmacokinetics, dose ranging and dose fractionation studies).

Urinary Tract Infection (Mouse)

  • Ascending pyelonephritis model using uropathogenic E. coli bacterial isolates and the diabetic mouse UTI model with Pseudomonas aeruginosa; enumeration of the bacterial titers in kidneys, bladder and urine.

Neisseria gonorrhoeae infection (Mouse)

  • In development

Sepsis / Inflammation (Mouse)

  • Murine cecal ligation and puncture model (CLP) with survival and biomarker endpoints.

Intra-abdominal Abscess Model (Rat / Mouse)

  • Mixed intra-abdominal infection with E. coli and B. fragilis

Infective Endocarditis Model (Rat)

  • Implanted catheter – S. aureus, Enterococcus


Systemic Antifungal Model (Mouse)

  • C. albicans, C. auris & C. kruseii (candidiasis)
  • Aspergillus fumigatus

Cutaneous Antifungal Model (Mouse)

  • Aspergillus fumigatus – Subcutaneous abscess & superficial skin infection
  • Fusarium spp. – in development


RSV Lung Infection (Mouse)

  • Respiratory syncytial virus lung burden model – pending

  • Additional protocols of interest can be developed at the request of the sponsor as required.